{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:45:49Z","timestamp":1791395149013,"version":"4.3.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science & Technology Commission","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-72541-2","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:16:10Z","timestamp":1778472970000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The multi-kinase inhibitor tinengotinib as monotherapy or combined with atezolizumab in advanced solid tumors: a phase Ib\/II trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Panpan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuoxing","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqian","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusuan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoshan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaohong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9614-6279","authenticated-orcid":false,"given":"Jiajia","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3798-7024","authenticated-orcid":false,"given":"Jifang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-2922","authenticated-orcid":false,"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"72541_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","volume":"17","author":"P Zhang","year":"2024","unstructured":"Zhang, P. et al. Targeting FGFR for cancer therapy. J. Hematol. Oncol. 17, 39 (2024).","journal-title":"J. Hematol. Oncol."},{"key":"72541_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/bjc.2012.581","volume":"108","author":"R Fisher","year":"2013","unstructured":"Fisher, R., Pusztai, L. & Swanton, C. Cancer heterogeneity: implications for targeted therapeutics. Br. J. cancer 108, 479\u2013485 (2013).","journal-title":"Br. J. cancer"},{"key":"72541_CR3","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.it.2018.05.001","volume":"39","author":"TK Kim","year":"2018","unstructured":"Kim, T. K., Herbst, R. S. & Chen, L. Defining and understanding adaptive resistance in cancer immunotherapy. Trends Immunol. 39, 624\u2013631 (2018).","journal-title":"Trends Immunol."},{"key":"72541_CR4","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa, G. K. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 21, 671\u2013684 (2020).","journal-title":"Lancet Oncol."},{"key":"72541_CR5","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/med.21399","volume":"36","author":"M Yan","year":"2016","unstructured":"Yan, M. et al. Aurora-A kinase: a potent oncogene and target for cancer therapy. Med Res Rev. 36, 1036\u20131079 (2016).","journal-title":"Med Res Rev."},{"key":"72541_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117585","volume":"180","author":"P Lorenc","year":"2024","unstructured":"Lorenc, P. et al. Physiological and tumor-associated angiogenesis: Key factors and therapy targeting VEGF\/VEGFR pathway. Biomed. Pharmacother. 180, 117585 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"72541_CR7","doi-asserted-by":"publisher","unstructured":"Owen, K. L., Brockwell, N. K. & Parker, B. S. JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression. Cancers (Basel) 11 https:\/\/doi.org\/10.3390\/cancers11122002 (2019).","DOI":"10.3390\/cancers11122002"},{"key":"72541_CR8","doi-asserted-by":"publisher","first-page":"e514","DOI":"10.1093\/oncolo\/oyad338","volume":"29","author":"SA Piha-Paul","year":"2024","unstructured":"Piha-Paul, S. A. et al. First-in-human phase i study of tinengotinib (tt-00420), a multiple kinase inhibitor, as a single agent in patients with advanced solid tumors. Oncologist 29, e514\u2013e525 (2024).","journal-title":"Oncologist"},{"key":"72541_CR9","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1200\/JCO.2023.41.16_suppl.3019","volume":"41","author":"SA Piha-Paul","year":"2023","unstructured":"Piha-Paul, S. A. et al. Preliminary safety and efficacy of tinengotinib tablets as monotherapy and combination therapy in advanced solid tumors: A phase Ib\/II clinical trial. J. Clin. Oncol. 41, 3019\u20133019 (2023).","journal-title":"J. Clin. Oncol."},{"key":"72541_CR10","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1200\/JCO.2024.42.3_suppl.434","volume":"42","author":"MM Javle","year":"2024","unstructured":"Javle, M. M. et al. Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: Results from phase II clinical trial. J. Clin. Oncol. 42, 434\u2013434 (2024).","journal-title":"J. Clin. Oncol."},{"key":"72541_CR11","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920953293","volume":"12","author":"A Saborowski","year":"2020","unstructured":"Saborowski, A., Lehmann, U. & Vogel, A. FGFR inhibitors in cholangiocarcinoma: what\u2019s now and what\u2019s next? Ther. Adv. Med Oncol. 12, 1758835920953293 (2020).","journal-title":"Ther. Adv. Med Oncol."},{"key":"72541_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman, M. & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237\u2013251 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"72541_CR13","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1158\/1535-7163.MCT-22-0012","volume":"22","author":"P Peng","year":"2023","unstructured":"Peng, P. et al. Tinengotinib (TT-00420), a novel spectrum-selective small-molecule kinase inhibitor, is highly active against triple-negative breast cancer. Mol. Cancer Ther. 22, 205\u2013214 (2023).","journal-title":"Mol. Cancer Ther."},{"key":"72541_CR14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10238-024-01460-7","volume":"24","author":"G Zhang","year":"2024","unstructured":"Zhang, G. et al. Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions. Clin. Exp. Med 24, 193 (2024).","journal-title":"Clin. Exp. Med"},{"key":"72541_CR15","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S2468-1253(25)00230-4","volume":"11","author":"M Javle","year":"2026","unstructured":"Javle, M. et al. Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial. Lancet Gastroenterol. Hepatol. 11, 137\u2013149 (2026).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"72541_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal, L. et al. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N. Engl. J. Med 388, 228\u2013239 (2023).","journal-title":"N. Engl. J. Med"},{"key":"72541_CR17","doi-asserted-by":"publisher","first-page":"S376","DOI":"10.1016\/j.annonc.2021.08.326","volume":"32","author":"M Droz Dit Busset","year":"2021","unstructured":"Droz Dit Busset, M. et al. 47P Derazantinib for patients with intrahepatic cholangiocarcinoma harboring FGFR2 fusions\/rearrangements: Primary results from the phase II study FIDES-01. Ann. Oncol. 32, S376 (2021).","journal-title":"Ann. Oncol."},{"key":"72541_CR18","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1200\/JCO.2023.41.4_suppl.572","volume":"41","author":"Y Guo","year":"2023","unstructured":"Guo, Y. et al. Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study. J. Clin. Oncol. 41, 572\u2013572 (2023).","journal-title":"J. Clin. Oncol."},{"key":"72541_CR19","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","volume":"30","author":"Q Wu","year":"2024","unstructured":"Wu, Q. et al. Landscape of clinical resistance mechanisms to fgfr inhibitors in fgfr2-altered cholangiocarcinoma. Clin. Cancer Res 30, 198\u2013208 (2024).","journal-title":"Clin. Cancer Res"},{"key":"72541_CR20","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.annonc.2024.11.017","volume":"36","author":"L Goyal","year":"2025","unstructured":"Goyal, L. et al. Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling. Ann. Oncol. 36, 414\u2013425 (2025).","journal-title":"Ann. Oncol."},{"key":"72541_CR21","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.annonc.2024.12.011","volume":"36","author":"L Goyal","year":"2025","unstructured":"Goyal, L. et al. A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma. Ann. Oncol. 36, 426\u2013443 (2025).","journal-title":"Ann. Oncol."},{"key":"72541_CR22","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh, D. Y. et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 1, EVIDoa2200015 (2022).","journal-title":"NEJM Evid."},{"key":"72541_CR23","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley, R. K. et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401, 1853\u20131865 (2023).","journal-title":"Lancet"},{"key":"72541_CR24","doi-asserted-by":"publisher","unstructured":"Okato, A. et al. FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression. J. Clin. Invest. 134, https:\/\/doi.org\/10.1172\/jci169241 (2024).","DOI":"10.1172\/jci169241"},{"key":"72541_CR25","doi-asserted-by":"publisher","first-page":"3431","DOI":"10.1158\/0008-5472.CAN-18-3397","volume":"79","author":"T Yin","year":"2019","unstructured":"Yin, T. et al. Aurora A inhibition eliminates myeloid cell-mediated immunosuppression and enhances the efficacy of anti-pd-l1 therapy in breast cancer. Cancer Res. 79, 3431\u20133444 (2019).","journal-title":"Cancer Res."},{"key":"72541_CR26","doi-asserted-by":"publisher","unstructured":"Liu, H. et al. Aurora kinase A inhibition potentiates platinum and radiation cytotoxicity in non-small-cell lung cancer cells and induces expression of alternative immune checkpoints. Cancers (Basel) 16, https:\/\/doi.org\/10.3390\/cancers16162805 (2024).","DOI":"10.3390\/cancers16162805"},{"key":"72541_CR27","doi-asserted-by":"publisher","unstructured":"Yarchoan, M. et al. Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers. J. Clin. Invest. 131, https:\/\/doi.org\/10.1172\/JCI152670 (2021).","DOI":"10.1172\/JCI152670"},{"key":"72541_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ejca.2021.11.012","volume":"162","author":"S Cousin","year":"2022","unstructured":"Cousin, S. et al. Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial. Eur. J. Cancer 162, 161\u2013169 (2022).","journal-title":"Eur. J. Cancer"},{"key":"72541_CR29","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1634\/theoncologist.2018-0044","volume":"23","author":"HT Arkenau","year":"2018","unstructured":"Arkenau, H. T. et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced or metastatic biliary tract cancer: nonrandomized, open-label, phase i trial (JVDF). Oncologist 23, 1407\u2013e1136 (2018).","journal-title":"Oncologist"},{"key":"72541_CR30","doi-asserted-by":"publisher","unstructured":"Necchi, A. et al. Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations. JNCI Cancer Spectr. 8, https:\/\/doi.org\/10.1093\/jncics\/pkae030 (2024).","DOI":"10.1093\/jncics\/pkae030"},{"key":"72541_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103625","volume":"9","author":"M Saleh","year":"2024","unstructured":"Saleh, M. et al. Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies. ESMO Open 9, 103625 (2024).","journal-title":"ESMO Open"},{"key":"72541_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101204","volume":"4","author":"V Subbiah","year":"2023","unstructured":"Subbiah, V. & Verstovsek, S. Clinical development and management of adverse events associated with FGFR inhibitors. Cell Rep. Med 4, 101204 (2023).","journal-title":"Cell Rep. Med"},{"key":"72541_CR33","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2023.41.16_suppl.3121","volume":"41","author":"S Pant","year":"2023","unstructured":"Pant, S. et al. Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis. J. Clin. Oncol. 41, 3121\u20133121 (2023).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72541-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72541-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72541-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:31:37Z","timestamp":1784183497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-72541-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["72541"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-72541-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.F. is employed by TransThera Sciences US, Inc. and has stock and other ownership interests in AstraZeneca. C.S., Y.Z. and Y.Y. are employed by TransThera Sciences (Nanjing), Inc. P.P. is employed by and has patents, royalties and other intellectual property in TransThera Sciences (Nanjing), Inc. All other authors declared no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"6290"}}